Harrington Heart & Vascular Institute

Thursday, July 13, 2017

University Hospitals appoints Mehdi H. Shishehbor, DO, PhD, MPH as new Director, Cardiovascular Interventional Center

CLEVELAND – University Hospitals Cleveland Medical Center and UH Harrington Heart & Vascular Institute announce the appointment of Mehdi H. Shishehbor, DO, PhD, MPH as Director of Cardiovascular Interventional Center effective Aug. 1, 2017.
He also will serve as a Co-Chair, Clinical Executive Committee with UH Cleveland Medical Center and work as the Co-Director, Vascular Center at UH Cleveland Medical Center and UH Harrington Heart & Vascular Institute. 
Dr. Shishehbor will receive patients in his new offices beginning Aug. 1.  More information can be found: http://www.uhhospitals.org/services/heart-and-vascular/institute/leadership/mehdi-h-shishehbor.

Wednesday, June 07, 2017

Harrington Discovery Institute announces Gund-Harrington Scholars

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio part of The Harrington Project for Discovery & Development, and the Foundation Fighting Blindness have announced their 2017 Gund-Harrington Scholars.
Harrington Discovery Institute partnerships are based on a shared mission to advance discoveries of new medicines that will improve human health, as well as, enhance each organization's ability to play a significant role in setting the scientific and innovation agenda in leading-edge research. These awards offer selected winners funding and drug development expertise to ensure the most promising treatments enter clinical trials where their safety and efficacy can be established.

Friday, June 02, 2017

Small molecule prevents blood clots without increasing bleeding risk

CLEVELAND – It may be possible to disrupt harmful blood clots in people at risk for heart attack or stroke without increasing their risk of bleeding, according to a new study published in Nature Communications.

The new research out of University Hospitals (UH) Cleveland Medical Center, Case Western Reserve University School of Medicine, and the Cleveland Clinic reveals a previously unknown cell receptor interaction that, when manipulated with therapeutic molecules, safely prevents blood clots. Approximately 100,000 Americans die annually from blood clots, or thrombosis, according to the Centers for Disease Control and Prevention.

“We have found a new thrombosis target that does not increase bleeding risk,” said senior author Daniel I. Simon, MD, President, UH Cleveland Medical Center, Herman K. Hellerstein Chair of Cardiovascular Research, and Professor of Medicine at Case Western Reserve School of Medicine. “Our discovery indicates that you can identify a new pathway and target that mediates blood clotting, but does not affect our body’s natural processes to stop bleeding, called hemostasis.”

Wednesday, May 24, 2017

Harrington Discovery Institute at University Hospitals opens call for Harrington Rare Disease Scholar Award

CLEVELAND – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – is pleased to announce its request for proposals for the Harrington Rare Disease Scholar Award. The Harrington Rare Disease Scholar Award supports breakthrough research for therapeutic discoveries in rare diseases. The program is sponsored by Takeda Pharmaceutical Company Limited (TSE: 4502) and overseen by Harrington Discovery Institute, a nonprofit initiative that helps academic researchers translate their most promising inventions into new medicines.

“We are excited to launch this new program with Takeda,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The Harrington Rare Disease Scholar Award provides a unique opportunity to advance cutting-edge research in rare diseases into life-saving treatments.”

Thursday, May 11, 2017

University Hospitals announces first commercial implant in the U.S. of The Evolut PRO transcatheter heart valve

CLEVELAND New surgical options are only as good as they make you feel once you leave the operating room. One of the biggest post-operative issues with the usually sound transaortic valve replacements (TAVR) was that the newly inserted valve allowed leakage that created poor outcomes.
University Hospitals announced that its surgeons completed the first commercial implant  in the United States of the newly FDA approved TAVR valve called the CoreValveEvolut PRO for the treatment of severe symptomatic aortic stenosis. Recently unveiled clinical data showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics for the self-expanding valve.
The Evolut PRO device features a unique valve design with an outer wrap that adds surface area contact between the valve and the native aortic annulus to further advance valve sealing performance. The biocompatible porcine pericardial tissue wrap, in addition to other design elements, is incorporated to address the occurrence of blood leaking through the sides of the valve.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.